ACTImmune™ is a test that informs you about your likelihood of benefitting from immunotherapy by checkpoint inhibitors. Recently, several studies have suggested that immunotherapy using immune checkpoint inhibitors which can restore or enhance immune response against tumor cells, showed a long-standing response in patients with different cancer types, including melanoma, lung cancer, and bladder cancer.
However, only 25-30% of patients are likely to benefit from the treatment. As the cost of Immune checkpoint inhibitors is very high, it is critical to have an accurate method to predict the response to these drugs. Studies have revealed that tumor with a higher mutational burden and increased number of tumor-specific protein (neoantigens) expressed on tumor cell surface can provide a more accurate prediction of responses to immunotherapy(Note1,2)
ACTImmune™ covers over 18,000 genes to determine mutational burden and the binding affinities between the neoantigens and the Major Histocompatibility Complex (MHC), which is essential for the acquired immune system to recognize foreign molecules.
Note 1. Snyder et al., N Engl J Med., 371:2189-2199, (2014)
Note 2. Rizvi et al., Science, 348:124-128 (2015)